JP2024028760A5 - - Google Patents
Info
- Publication number
- JP2024028760A5 JP2024028760A5 JP2023199616A JP2023199616A JP2024028760A5 JP 2024028760 A5 JP2024028760 A5 JP 2024028760A5 JP 2023199616 A JP2023199616 A JP 2023199616A JP 2023199616 A JP2023199616 A JP 2023199616A JP 2024028760 A5 JP2024028760 A5 JP 2024028760A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical product
- product according
- weekly
- dose
- administration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762594747P | 2017-12-05 | 2017-12-05 | |
| US62/594,747 | 2017-12-05 | ||
| US201862725612P | 2018-08-31 | 2018-08-31 | |
| US62/725,612 | 2018-08-31 | ||
| US201862745000P | 2018-10-12 | 2018-10-12 | |
| US62/745,000 | 2018-10-12 | ||
| JP2020531164A JP7827407B2 (ja) | 2017-12-05 | 2018-12-05 | アルギナーゼ１欠損症を治療するための方法及び組成物 |
| PCT/US2018/063982 WO2019113157A1 (en) | 2017-12-05 | 2018-12-05 | Method and composition for treating arginase 1 deficiency |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020531164A Division JP7827407B2 (ja) | 2017-12-05 | 2018-12-05 | アルギナーゼ１欠損症を治療するための方法及び組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024028760A JP2024028760A (ja) | 2024-03-05 |
| JP2024028760A5 true JP2024028760A5 (cg-RX-API-DMAC10.html) | 2026-05-15 |
Family
ID=64734275
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020531164A Active JP7827407B2 (ja) | 2017-12-05 | 2018-12-05 | アルギナーゼ１欠損症を治療するための方法及び組成物 |
| JP2023199616A Pending JP2024028760A (ja) | 2017-12-05 | 2023-11-27 | アルギナーゼ１欠損症を治療するための方法及び組成物 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020531164A Active JP7827407B2 (ja) | 2017-12-05 | 2018-12-05 | アルギナーゼ１欠損症を治療するための方法及び組成物 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US11717562B2 (cg-RX-API-DMAC10.html) |
| EP (1) | EP3720476A1 (cg-RX-API-DMAC10.html) |
| JP (2) | JP7827407B2 (cg-RX-API-DMAC10.html) |
| KR (2) | KR20260047622A (cg-RX-API-DMAC10.html) |
| CN (3) | CN120661640A (cg-RX-API-DMAC10.html) |
| AU (1) | AU2018378485B2 (cg-RX-API-DMAC10.html) |
| CA (1) | CA3084801A1 (cg-RX-API-DMAC10.html) |
| MX (2) | MX2020005933A (cg-RX-API-DMAC10.html) |
| TW (1) | TWI878212B (cg-RX-API-DMAC10.html) |
| WO (1) | WO2019113157A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3449935A1 (en) * | 2017-08-31 | 2019-03-06 | Erytech Pharma | Arginine deiminase encapsulated inside erythrocytes and their use in treating cancer and arginase-1 deficiency |
| TWI878212B (zh) | 2017-12-05 | 2025-04-01 | 瑞典商伊梅爾迪卡製藥公司 | 用於治療精胺酸酶1缺乏症之方法及組合物 |
| WO2020081994A1 (en) * | 2018-10-19 | 2020-04-23 | Aerase, Inc. | Arginine depletion therapy for treatment of gamt deficiency |
| BR112022003633A2 (pt) * | 2019-08-30 | 2022-06-07 | Aeglea Biotherapeutics Inc | Métodos para produção de arginase 1 recombinante humana e usos da mesma |
| CN114350721B (zh) * | 2021-11-30 | 2024-05-24 | 新泰市佳禾生物科技有限公司 | 微生物酶法生产l-鸟氨酸的方法 |
| CN114196712B (zh) * | 2021-11-30 | 2024-04-02 | 新泰市佳禾生物科技有限公司 | 一种固定化酶法生产l-鸟氨酸的方法 |
| CN114214353B (zh) * | 2021-11-30 | 2023-07-18 | 新泰市佳禾生物科技有限公司 | 一种发酵生产人重组精氨酸酶i的方法 |
| CN116179452A (zh) * | 2022-07-11 | 2023-05-30 | 山东第一医科大学(山东省医学科学院) | 一种用于治疗精氨酸酶缺乏症的工程益生菌及其构建方法和应用 |
| WO2025171346A1 (en) * | 2024-02-08 | 2025-08-14 | University Of Florida Research Foundation, Incorporated | Indoleamine 2,3-dioxygenase variants |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH02117383A (ja) | 1988-10-26 | 1990-05-01 | Tosoh Corp | ヒトアルギナーゼの製造方法 |
| US5780286A (en) | 1996-03-14 | 1998-07-14 | Smithkline Beecham Corporation | Arginase II |
| WO2003063780A2 (en) | 2002-01-25 | 2003-08-07 | Cancer Treatments International | Therapeutic composition for treatment of cancer by arginine depletion |
| HK1053577A2 (en) | 2002-06-20 | 2003-10-10 | Bio-Cancer Treatment International Limited | Pharmaceutical composition and method of treatment of human malignanices with arginine deprivation |
| GB0315248D0 (en) * | 2003-06-30 | 2003-08-06 | Hoffmann La Roche | HCV regulated protein expression |
| FR2873925B1 (fr) | 2004-08-05 | 2006-10-13 | Erytech Pharma Soc Par Actions | Procede et dispositif de lyse-rescellement pour l'incorporation de principe actif notamment asparaginase ou inositol hexaphosphate, dans des erythrocytes |
| CN1745847A (zh) | 2004-09-08 | 2006-03-15 | 康达医药科技有限公司 | 用精氨酸酶治疗肝炎的药物组合物和方法 |
| EP1974044B1 (en) | 2005-12-12 | 2011-01-26 | CANJI, Inc. | Adenoviral expression vectors having an expression cassette in the e1 region and an inactivated e2b polymerase |
| PL3064579T3 (pl) | 2008-10-31 | 2021-07-05 | Aerase, Inc. | Kompozycje farmaceutyczne i zastosowania medyczne uzyskanych metodami inżynierii ludzkich arginaz |
| US9382525B2 (en) * | 2009-03-26 | 2016-07-05 | The Hong Kong Polytechnic University | Site-directed pegylation of arginases and the use thereof as anti-cancer and anti-viral agents |
| AU2010242422B2 (en) | 2009-03-26 | 2014-12-04 | The Hong Kong Polytechnic University | Site-directed pegylation of arginases and the use thereof as anti-cancer and anti-viral agents |
| CA2766039A1 (en) | 2009-06-29 | 2011-01-20 | The Board Of Regents Of The University Of Texas System | Arginase formulations and methods |
| WO2012061015A2 (en) | 2010-11-03 | 2012-05-10 | Scott & White Healthcare | L-citrulline supplementation during arginine depletion therapy with arginase |
| CN103184209B (zh) | 2011-12-27 | 2015-09-16 | 拜奥生物科技（上海）有限公司 | 人精氨酸酶和聚乙二醇化人精氨酸酶及其应用 |
| WO2014093694A1 (en) | 2012-12-12 | 2014-06-19 | The Broad Institute, Inc. | Crispr-cas nickase systems, methods and compositions for sequence manipulation in eukaryotes |
| FR3005420B1 (fr) | 2013-05-07 | 2015-09-18 | Erytech Pharma | Procede de stabilisation de suspensions d'erythrocytes encapsulant un principe actif, suspensions obtenues. |
| LT3105328T (lt) | 2014-02-11 | 2020-07-10 | The Regents Of The University Of Colorado, A Body Corporate | Daugiakomponentis genomo konstravimas, sudarantis sąlygas crispr |
| EP3134546A4 (en) | 2014-04-24 | 2017-12-06 | Dana-Farber Cancer Institute, Inc. | Tumor suppressor and oncogene biomarkers predictive of anti-immune checkpoint inhibitor response |
| EP3137103B1 (en) * | 2014-04-29 | 2021-10-20 | Bio-Cancer Treatment International Ltd. | Methods and compositions for modulating the immune system with arginase i |
| EP2982758A1 (en) | 2014-08-04 | 2016-02-10 | Centre Hospitalier Universitaire Vaudois (CHUV) | Genome editing for the treatment of huntington's disease |
| EP3186281B1 (en) | 2014-08-28 | 2019-04-10 | Halozyme, Inc. | Combination therapy with a hyaluronan-degrading enzyme and an immune checkpoint inhibitor |
| JP2019508037A (ja) | 2016-02-16 | 2019-03-28 | イェール ユニバーシティーＹａｌｅ Ｕｎｉｖｅｒｓｉｔ | 標的化遺伝子編集を増強するための組成物およびその使用方法 |
| KR102646323B1 (ko) | 2016-05-06 | 2024-03-13 | 이뮤노포지 주식회사 | 제어된 지속 방출을 위한 elp 융합 단백질 |
| TWI878212B (zh) | 2017-12-05 | 2025-04-01 | 瑞典商伊梅爾迪卡製藥公司 | 用於治療精胺酸酶1缺乏症之方法及組合物 |
| BR112022003633A2 (pt) | 2019-08-30 | 2022-06-07 | Aeglea Biotherapeutics Inc | Métodos para produção de arginase 1 recombinante humana e usos da mesma |
| CN119301247A (zh) | 2022-04-11 | 2025-01-10 | 伊梅尔迪卡制药公司 | 精氨酸酶1缺乏症的治疗 |
-
2018
- 2018-12-05 TW TW107143773A patent/TWI878212B/zh active
- 2018-12-05 US US16/210,248 patent/US11717562B2/en active Active
- 2018-12-05 EP EP18821957.0A patent/EP3720476A1/en active Pending
- 2018-12-05 WO PCT/US2018/063982 patent/WO2019113157A1/en not_active Ceased
- 2018-12-05 KR KR1020267007681A patent/KR20260047622A/ko active Pending
- 2018-12-05 CN CN202510809152.4A patent/CN120661640A/zh active Pending
- 2018-12-05 MX MX2020005933A patent/MX2020005933A/es unknown
- 2018-12-05 CN CN201880079119.9A patent/CN111787941A/zh active Pending
- 2018-12-05 CA CA3084801A patent/CA3084801A1/en active Pending
- 2018-12-05 CN CN202510809272.4A patent/CN120643682A/zh active Pending
- 2018-12-05 KR KR1020207019283A patent/KR20200122298A/ko not_active Ceased
- 2018-12-05 JP JP2020531164A patent/JP7827407B2/ja active Active
- 2018-12-05 AU AU2018378485A patent/AU2018378485B2/en active Active
-
2020
- 2020-07-13 MX MX2025006207A patent/MX2025006207A/es unknown
-
2023
- 2023-06-29 US US18/344,083 patent/US12673093B2/en active Active
- 2023-11-27 JP JP2023199616A patent/JP2024028760A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6247276B2 (ja) | 二重に誘導体化されたキトサンナノ粒子並びにｉｎｖｉｖｏの遺伝子送達のためのその作製および使用方法 | |
| JP2019524670A (ja) | 治療薬の送達のための組成物及び方法 | |
| ZA200704744B (en) | Nanoparticulate and controlled release compositions comprising a cephalosporin | |
| CN113382737A (zh) | 抗病毒前药及其纳米制剂 | |
| US20210316002A1 (en) | Compositions and methods for drug delivery and treating viral infections | |
| US12178915B2 (en) | High concentration formulations of anti-CSF1 and anti-CSF1R antibodies | |
| IL318548A (en) | Methods for treating muscular dystrophy with casimersen | |
| JP7667931B2 (ja) | Ｇａｍｔ欠損症の治療のためのアルギニン枯渇療法 | |
| WO2021168996A1 (en) | Catalase nanocapsules and methods for use | |
| US20250325674A1 (en) | AUTOIMMUNE DISEASE THERAPEUTIC AGENT INCLUDING OLIGONUCLEOTIDE THAT SELECTIVELY BINDS TO IFN-y, AND SAID OLIGONUCLEOTIDE | |
| CN109996554B (zh) | 新型抗微生物和抗癌疗法 | |
| JPH0618781B2 (ja) | 感染症治療剤 | |
| JP2008512399A5 (cg-RX-API-DMAC10.html) | ||
| JP2003519088A (ja) | Ｈｉｖ感染患者の治療および予防のためのｇｓｓｇレダクターゼの使用 | |
| KR102314558B1 (ko) | 베네토클락스의 수용성 고분자 유도체 | |
| JP2023116456A (ja) | 強皮症関連血管障害を治療または改善するための組成物および方法 | |
| AU2021221064B2 (en) | Pharmaceutical composition for inhibiting inflammatory response comprising hydroxyurea | |
| CN116367843A (zh) | 病毒抑制剂 | |
| CN1122534C (zh) | 减少药物副作用的方法 | |
| US11918552B2 (en) | N-acetylcysteine for use as antibacterial agent | |
| WO2026006187A1 (en) | Composition and method of treating t-cell lymphoma | |
| JP2023550079A5 (cg-RX-API-DMAC10.html) | ||
| WO2019198087A1 (en) | Compositions and methods for treatment of demyelination | |
| NZ774138B2 (en) | Medicament for mitigating conditions and/or suppressing onset of peripheral neuropathy induced by anti-malignant tumor agent | |
| JP2000095703A (ja) | Ｈｔｌｖ―１関連疾患用経口治療剤及び／又は予防剤 |